Skip to main content
. 2003 Sep 9;89(6):983–991. doi: 10.1038/sj.bjc.6601160

Figure 4.

Figure 4

Progression-free survival in patients receiving trastuzumab-based treatment for Her-2/neu overexpressing metastatic breast cancer in accordance to activation status of Her-2/neu. Full line: unphosphorylated Her-2/neu, dotted line: phosphorylated Her-2/neu (log-rank test P<0.0095).